Home ›
Sarcoma Trials ›
NCT05679921
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
Trial Details
NCT ID NCT05679921
Phase PHASE2
Sponsor Yonsei University
Status RECRUITING
Cancer Type Sarcoma
Interventions
Locations (sample) Seoul, South Korea|37.566,126.9784
Key Eligibility Criteria
Histologically confirmed Soft Tissue Sarcoma(STS) progression to 1 or 2 (less than 3) prior chemotherapy : Exclude pazopanib-resistant subtype - em… Age \> 19 years, ≤80 years at time of study entry Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 7 days before screening) Measurable disease by Response Evaluation Criteria in Solid Tumors Version 1.1
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →